pills-istock-525984851-1-1
sprng23 / iStockphoto.com
25 July 2018Big Pharma

CJEU clarifies ‘basic patent’ meaning in SPC dispute

Earlier today, the Court of Justice of the European Union (CJEU) clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of regulation 469/2009 (the SPC regulation).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
30 April 2020   The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.
Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Big Pharma
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.

More on this story

Big Pharma
30 April 2020   The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.
Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Big Pharma
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.

More on this story

Big Pharma
30 April 2020   The Court of Justice of the European Union has handed down its decision in Royalty Pharma, providing highly-anticipated guidance on supplementary protection certificates.
Big Pharma
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Big Pharma
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.